E-mail

E-mail a Wiley Online Library Link

K.A. Papp, C.E.M. Griffiths, K. Gordon, M. Lebwohl, P.O. Szapary, Y. Wasfi, D. Chan, M.-C. Hsu, V. Ho, P.D. Ghislain, B. Strober, K. Reich and on behalf of the PHOENIX 1, PHOENIX 2 and ACCEPT Investigators Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up British Journal of Dermatology 168

Version of Record online: 25 MAR 2013 | DOI: 10.1111/bjd.12214

What’s already known about this topic?

  •  Short-term studies of ustekinumab in patients with moderate-to-severe psoriasis indicated a favourable benefit–risk profile. Long-term safety evaluations are needed to inform patient management decisions.

What does this study add?

  •  This report evaluated the largest psoriasis clinical trial cohort to date with the longest duration of follow-up. Safety outcomes after 5 years of ustekinumab treatment are consistent with shorter-term reports and are generally comparable with observations from studies of other biologics in patients with psoriasis.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH